# Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth

> **NCT06648850** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Applied Biology, Inc.** · enrollment: 1120 (estimated)

## Conditions studied

- Telogen Effluvium
- Female Pattern Hair Loss
- Female Pattern Hair Loss, Androgenic Alopecia
- Male Pattern Baldness
- Androgenetic Alopecia
- Androgenetic Alopecia (AGA)

## Interventions

- **DRUG:** DA-001
- **OTHER:** Placebo
- **DRUG:** Phenylephrine
- **OTHER:** DA-001 Topical + DA-005 Oral (HIF-1α supplement)
- **OTHER:** DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)
- **DRUG:** Phenylephrine Topical 0.25% + Intact Pro Topical
- **OTHER:** Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement)

## Key facts

- **NCT ID:** NCT06648850
- **Lead sponsor:** Applied Biology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-03-19
- **Final completion:** 2027-04-26
- **Target enrollment:** 1120 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06648850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06648850, "Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06648850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*